Now there’s Axumin (fluciclovine F 18), an FDA-approved positron emission tomography (PET) scan that works by analyzing the metabolic activity specific to prostate cancer. PET is a nuclear medicine imaging test that utilizes a tiny amount of radioactive material, called a radiotracer, that is attracted to tumor cells, enabling earlier cancer discovery than many other types of scans.